Research Peptides

Seliciclib (Roscovitine)

Seliciclib (R-Roscovitine, CYC202) is a potent and selective inhibitor of cyclin-dependent kinases (CDKs), primarily targeting CDK2/cyclin E, CDK7/cyclin H, and CDK9/cyclin T1. By blocking these key cell cycle regulators, Seliciclib arrests cell proliferation, induces apoptosis in cancer cells, and modulates transcription. Originally developed as an anti-cancer agent, Seliciclib has undergone Phase II clinical trials for non-small cell lung cancer and nasopharyngeal carcinoma. Beyond oncology, it shows promise in research on inflammatory diseases, viral infections (by inhibiting CDK9-dependent viral transcription), and neurodegenerative conditions.

Technical Specifications

Sequence / StructureNon-peptide small molecule (2-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine)
Molecular Weight354.44 g/mol
Purity≥99%
AppearanceOff-white to pale yellow powder
StorageStore at -20°C, protect from light
SolubilitySoluble in DMSO and ethanol

Application Areas

  • CDK inhibition research
  • Cell cycle regulation studies
  • Anti-cancer research
  • Transcription modulation studies
  • Anti-viral research

Published Research on Seliciclib (Roscovitine)

Meijer L, Borgne A, Mulner O, et al. (1997) — Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2, cdk5, and cdk7. Eur J Biochem. DOI: 10.1111/j.1432-1033.1997.0527a.x

Benson C, White J, De Bono J, et al. (2007) — A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer. DOI: 10.1038/sj.bjc.6603461

Frequently Asked Questions About Seliciclib (Roscovitine)

Seliciclib (Roscovitine) is a selective CDK2/7/9 inhibitor that blocks cell proliferation and induces apoptosis, studied primarily as an anti-cancer compound.

Our wholesale Seliciclib is ≥99% purity with HPLC verification.

Applications include CDK biology, cell cycle research, anti-cancer studies, transcription regulation, and anti-viral research.

Store at -20°C protected from light. Prepare stock solutions in DMSO.

Contact our team for MOQ and bulk pricing.

No, it is a purine-based small molecule CDK inhibitor, commonly offered alongside peptide products for overlapping research applications.

Related Research Peptides

Request Price List